CDEK by Data4ThePeople
Sign in Sign up
← All organizations
BTG

BTG

For profitContributed to NMEWebsite ↗

Also known as: Bio-Technology General Israel Ltd. (BTG) | BTG International Inc. | BTG INTERNATIONAL INC | BTG INTL | CellMed AG, a subsidiary of BTG plc. | PROVENSIS

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jan 1, 2000

First marketed drug

Jun 1, 1993

First NDA

Oct 2, 2000

Last known activity

Jan 1, 2022

Acquired by Boston Scientific Corporation on Nov 20, 2018

Timeline

1990s

  1. Jan 1, 1991

    BTG— Founded

2000s

  1. Oct 2, 2000

    crotalidae polyvalent immune fab (ovine)— NDA Organization

  2. Aug 31, 2001

    digoxin immune fab (ovine)— NDA Secondary Org

  3. Mar 8, 2005

    CellMed AG— Acquired

  4. Dec 15, 2006

    hydroxocobalamin— Marketing Organization

  5. Jan 1, 2008

    Protherics PLC— Acquired

2010s

  1. Jan 1, 2010

    Biocompatibles International plc— Acquired

  2. Jan 1, 2013

    Ekos Corp— Acquired

  3. Jan 1, 2014

    PneumRx— Acquired

  4. May 5, 2016

    Galil Medical— Acquired

  5. Oct 5, 2017

    Roxwood Medical— Acquired

  6. Sep 7, 2018

    Novate Medical— Acquired

  7. Nov 20, 2018

    Boston Scientific Corporation— Acquired By

Drugs by trial phase (37 distinct, 54 trials)

Phase 3 (1 own, 3 via acquisition)

Indications

Studied for

Marketed drugs (8)

Subsidiaries (8 direct, 9 total across the full acquisition tree)

Recent trials (49)

Details

Founded
London, GB Jan 1, 1991
First NDA
Oct 2, 2000
Last known activity
Jan 1, 2022

Designations held

  • Orphan drug